NCT03037489View on ClinicalTrials.gov

A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

November 28, 2017

Study Completion Date

November 28, 2017

Conditions
Osteoarthritis, Knee
Interventions
DRUG

MIV-711

MIV-711 administered orally once daily

Trial Locations (4)

Unknown

MC Comac Medical, Sofia

LCC ARENSIA Exploratory Medicine, Tbilisi

PAREXEL Berlin Early Phase Clinical Unit, Berlin

LCC ARENSIA Exploratory Medicine, Chisinau

Sponsors

Lead Sponsor

Medivir
All Listed Sponsors
lead

Medivir

INDUSTRY

NCT03037489 - A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients | Biotech Hunter | Biotech Hunter